AdAlta (1AD) 2020年年度报告「ASX」.pdf

1、ANNUAL REPORTFOR THE YEAR ENDED 30 JUNE 2020ADALTA LTDABN 92 120 332 925CORPORATE DIRECTORYDIRECTORSDr Paul MacLemanNon-Executive ChairmanDr Timothy OldhamChief Executive Officer and Managing Director(appointed 8/10/2019)Ms Elizabeth McCallNon-Executive Director Dr Robert PeachNon-Executive Director

2、Dr David FullerNon-Executive Director (appointed 22/7/2020)Dr James WilliamsAlternate Director to Elizabeth McCall (transitioned to Alternate Director 27/03/2020)COMPANY SECRETARYCameron JonesREGISTERED OFFICEUnit 152 Park DriveBundoora VIC 3083Telephone:+61 3 9479 5159 Email:.auWebsite:.auSTOCK EXC

3、HANGEAustralian Securities Exchange LimitedLevel 4,North Tower Rialto525 Collins StreetMelbourne VIC 3000ASX CODE1ADSHARE REGISTRYAutomic Registry Services Level 5126 Phillip StreetSydney NSW 2000Telephone:1300 288 664Website:.auAUDITORButler Settineri(Audit)Pty Ltd Unit 16 First Floor100 Railway Ro

4、adSubiaco WA 6008BANKERSWestpac Banking CorporationSOLICITORSK&L GatesLevel 25 South Tower 525 Collins StreetMelbourne VIC 3000AdAlta Limited Annual Report 20202CONTENTSCHAIRS LETTER 05CEO AND MANAGING DIRECTOR LETTER 06DIRECTORS REPORT 07AUDITORS INDEPENDENCE DECLARATION 26CORPORATE GOVERNANCE STAT

5、EMENT 27STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME 28STATEMENT OF FINANCIAL POSITION 29STATEMENT OF CHANGES IN EQUITY 30STATEMENT OF CASH FLOWS 31NOTES TO THE FINANCIAL STATEMENTS 32DIRECTORS DECLARATION 53INDEPENDENT AUDITORS REPORT 54SHAREHOLDER INFORMATION 59AdAlta Limited Annual

6、Report 20203AdAlta Limited Annual Report 20204CHAIRS LETTERIn the FY2019 Annual Report I noted that the year to come would see AdAlta make the transition to being a clinical stage biopharmaceutical development company.I am delighted to report that in FY2020 we have achieved that goal with lead asset